Moleculin Biotech Inc (MBRX.OQ)
MBRX.OQ on NASDAQ Stock Exchange Capital Market
1.85USD
20 Apr 2018
1.85USD
20 Apr 2018
Change (% chg)
$-0.02 (-1.07%)
$-0.02 (-1.07%)
Prev Close
$1.87
$1.87
Open
$1.85
$1.85
Day's High
$1.85
$1.85
Day's Low
$1.84
$1.84
Volume
2,867
2,867
Avg. Vol
136,930
136,930
52-wk High
$3.74
$3.74
52-wk Low
$0.71
$0.71
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.00 | -0.150 |
| Sep '17 | 0.00 | -0.140 | |
| Jun '17 | 0.00 | -0.192 | |
| Mar '17 | 0.00 | -0.023 | |
| FY 2016 | Dec '16 | 0.00 | -0.311 |
| Sep '16 | 0.00 | -0.124 | |
| Jun '16 | 0.00 | -0.088 | |
| Mar '16 | 0.00 | -0.023 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 1 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-19 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 1 | -0.14 | -0.14 | -0.14 | -- |
| Quarter Ending Sep-18 | 1 | -0.14 | -0.14 | -0.14 | -- |
| Year Ending Dec-18 | 1 | -0.57 | -0.57 | -0.57 | -0.36 |
| Year Ending Dec-19 | 1 | -0.62 | -0.62 | -0.62 | -- |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 30.95 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 40.70 | 45.72 | |
| P/E Low - Last 5 Yrs. | -- | 23.63 | 24.22 | |
| Beta | -- | 0.89 | 0.88 | |
| Price to Sales (TTM) | -- | 3.94 | 5.71 | |
| Price to Book (MRQ) | 2.57 | 4.80 | 5.37 | |
| Price to Tangible Book (MRQ) | 6.14 | 5.61 | 6.95 | |
| Price to Cash Flow (TTM) | -- | 22.91 | 23.32 | |
| % Owned Institutions | 5.13 | 1.21 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.56 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 1.57 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 4.47 | 5.32 | |
| Payout Ratio(TTM) | -- | 45.35 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 3.69 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 4.83 | 5.69 | |
| Sales - 5 Yr. Growth Rate | -- | 10.08 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -138.19 | 16.36 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.87 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.52 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.12 | 2.19 |
| Current Ratio (MRQ) | 5.51 | 2.90 | 2.98 |
| LT Debt to Equity (MRQ) | 0.00 | 9.88 | 12.18 |
| Total Debt to Equity (MRQ) | 0.00 | 13.86 | 16.45 |
| Interest Coverage (TTM) | -- | 35.89 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 54.81 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.15 | 52.20 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.57 | 10.96 | |
| Operating Margin (TTM) | -- | 14.36 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.52 | 6.40 | |
| Pre-Tax Margin (TTM) | -- | 14.82 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.90 | 6.81 | |
| Net Profit Margin (TTM) | -- | 11.08 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.20 | 3.09 | |
| Effective Tax Rate (TTM) | -- | 23.16 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.42 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 938,079,949 | 846,830,978 | |
| Net Income/Employee (TTM) | -3,304,195 | 110,368,367 | 99,616,195 | |
| Receivable Turnover (TTM) | -- | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.59 | 3.35 | |
| Asset Turnover (TTM) | 0.00 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -32.65 | 11.40 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -- | 12.91 | 12.31 | |
| Return on Investment (TTM) | -35.48 | 14.84 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -- | 16.88 | 16.10 | |
| Return on Equity (TTM) | -36.21 | 16.34 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | -- | 17.98 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -1,458.84 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Moleculin Biotech Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -6.82 | -10.03 | 36 | 23 |
| 13 Week | 69.66 | 61.39 | 99 | 34 |
| 26 Week | 192.86 | 170.60 | 99 | 29 |
| 52 Week | -51.86 | -59.20 | 15 | 12 |
| YTD | 7.89 | -5.25 | 99 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Moleculin Biotech Inc - Has Been Able To Show Promising Tumor Suppression Activity With Its Inhibitor Of Glycolysis, Wp1122
- BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor
- BRIEF-Moleculin Announces Polish Approval For Leukemia Clinical Trial
- BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA
- BRIEF-Moleculin Biotech Q3 loss per share $0.14
Institutional Holders
| % Shares Owned: | 8.80% |
| # of Holders: | 16 |
| Total Shares Held: | 2,266,545 |
| 3 Mo. Net Change: | 1,502,350 |
| # New Positions: | 1 |
| # Closed Positions: | 0 |
| # Increased Positions: | 1 |
| # Reduced Positions: | 0 |
| # Net Buyers: | 1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.